Ilex Medical

Ilex Medical Net Margin

The Net Profit Margin of Ilex Medical (ILX.TA) as of Oct 22, 2026 is 4.24 %. In the previous year, Net Profit Margin was 5.55 % — a change of -23.74% (lower).

Net Margin

4.24 %

YoY

-23.74%

Last updated:

Net Profit Margin of Ilex Medical is 2024 4.24 % . Net Profit Margin of Ilex Medical was 2023 5.55 % . It decreases by -23.74% lower compared to the previous year.

For Ilex Medical, the net margin of 4.2% is down versus 12.7% a few years ago.

The Ilex Medical Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
6.76 ILS
Jan 1, 2018
7.82 ILS
Jan 1, 2019
9.50 ILS
Jan 1, 2020
12.74 ILS
Jan 1, 2021
18.61 ILS
Jan 1, 2022
11.70 ILS
Jan 1, 2023
5.55 ILS
Jan 1, 2024
4.24 ILS
The Ilex Medical Net Margin history
YEARNet MarginYoY
4.24 %-23.74%
5.55 %-52.55%
11.70 %-37.12%
18.61 %+46.04%
12.74 %+34.08%
9.50 %+21.62%
7.82 %+15.69%
6.76 %+26.79%
5.33 %-14.78%
6.25 %+22.43%
5.11 %-10,713.67%
-0.05 %+1.67%
-0.05 %-162.29%
0.08 %-35.01%
0.12 %-4.88%
0.12 %+40.48%
0.09 %-29.24%
0.12 %+7.05%
0.12 %+32.63%
0.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ilex Medical Stock analysis

What does Ilex Medical do? Ilex Medical Ltd supplies in vitro diagnostic equipment and laboratory management software, targeting healthcare providers and laboratories. The company offers nucleic acid testing (NAT) blood screening solutions, cancer screening products, retro virus load monitoring, TB and STD testing systems, and blood sugar monitoring devices. Its subsidiaries include Ilex South Africa, Orsyx-LIS, Ilex BioTech Ltd, and Medtechnica Ltd, which support its diagnostic equipment and software distribution. Healthcare facilities and diagnostic laboratories purchase these products for clinical testing and patient management. Ilex Medical Ltd's revenue streams come from selling diagnostic equipment, reagent systems, and laboratory information systems (LIS) to healthcare institutions. The firm's NAT blood screening solutions and infectious disease testing systems are key products for blood banks and public health labs. Subsidiaries like Orsyx-LIS provide specialized laboratory management software, enhancing the company's offerings in the diagnostic software segment. Hospitals and clinics rely on these solutions for efficient diagnostic workflows. The company serves segments including hospitals, blood banks, public health laboratories, and clinics focused on infectious disease management. Products such as cancer screening tools and retro virus load systems are sold to specialized medical facilities. Ilex South Africa and Medtechnica Ltd extend the company's reach in regional markets, supporting localized sales and service. Diagnostic software from Orsyx-LIS is integrated into laboratory workflows for improved data management. Ilex Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ilex Medical stock

Net Profit Margin of Ilex Medical is 4.24 % in 2024.

Net Profit Margin of Ilex Medical changed from 5.55 % to 4.24 %, representing a -23.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Ilex Medical since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Ilex Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Ilex Medical

All Key Metrics — Ilex Medical